Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Parkinson's drug trial halted early: what happened?

NCT ID NCT06822517

Disease control Sponsor: Ventus Therapeutics U.S., Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called VENT-02 in 29 people with mild to moderate Parkinson's disease. The drug aims to reduce brain inflammation by blocking a protein called NLRP3. The trial was terminated early, so we don't have clear results on whether it helps symptoms or slows the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VENT-02 (an NLRP3 inhibitor)
What this could lead to
If successful, this could point toward a treatment that slows Parkinson's progression by targeting inflammation in the brain.
What could go wrong
This was a very early, small trial that was terminated, so results are limited. It is unclear if VENT-02 is safe or effective for Parkinson's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

29 people

The number who actually took part.

Started

Mar 2025

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 45 to 90 years of age, inclusive. * Body weight and body mass index (BMI) within the range of 100 to 265 pounds (45 to 120 kg) and 18 to 34 kg/m2 (inclusive), respectively. * A diagnosis of idiopathic PD according to United Kingdom (UK) Brain Bank or Movement Disorder Society (MDS) criteria with bradykinesia and ≥ 1 additional cardinal sign of PD (e.g., resting tremor, rigidity). * A diagnosis of PD for ≤ 7 years at Screening. * A modified Hoehn \& Yahr stage 1 to 2.5. * If presently receiving treatment for PD, must be on a stable dose for ≥ 2 weeks prior to dosing, with no expected change in this regimen for the duration of the study. * If presently taking any non-PD concomitant medications, must be on a stable dose for ≥ 2 weeks prior to dosing. Exclusion Criteria: * Any clinically significant abnormality at Screening * A positive serology for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV) 1/2 at Screening. * A significant neurological disease affecting the central nervous system, other than PD, that may affect cognition or ability to complete the study, including but not limited to dementias, severe and repetitive past (up to 5 years) head trauma, normal pressure hydrocephalus, or epilepsy or recurrent seizures (except febrile childhood seizures), as determined by the investigator. * Current serious or unstable illnesses, that, in the investigator's opinion, could compromise patient safety and ability to comply with study procedures, or has a life expectancy of \< 24 months. * A history of suicidal ideation or previous suicide attempt in the 12 months prior to Screening or is clinically judged by the investigator to be at serious risk for suicide as assessed by medical history, examination, or the C-SSRS. * A contraindication (e.g., current use of anticoagulants) that would prohibit a lumbar puncture (LP). * Currently enrolled in any other interventional clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study, as assessed by the investigator. * Has participated in a clinical trial involving an investigational product within 30 days or 5 half-lives (whichever is longer) prior to dosing. * Has levodopa-induced dyskinesias lasting for \> 25% of waking day or dyskinesias interfering with many daily activities. * Has dysphagia to the extent that it would affect the patient's ability to swallow the investigational medicinal product (IMP). * Has a parkinsonian syndrome, including atypical parkinsonism. * Is a known carrier (i.e., confirmed by historical medical documentation) of familial PD genes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • Investigative Site

    Fountain Valley, California, 92708, United States

  • Investigative Site

    San Jose, California, 95124, United States

  • Investigative Site

    West Hills, California, 91307, United States

  • Investigative Site

    Englewood, Colorado, 80113, United States

  • Investigative Site

    Aventura, Florida, 33180, United States

  • Investigative Site

    Boca Raton, Florida, 33486, United States

  • Investigative Site

    Coral Gables, Florida, 33134, United States

  • Investigative Site

    Coral Springs, Florida, 33067, United States

  • Investigative Site

    Cutler Bay, Florida, 33189, United States

  • Investigative Site

    Daytona Beach, Florida, 32117, United States

  • Investigative Site

    Doral, Florida, 33178, United States

  • Investigative Site

    Jacksonville, Florida, 32256, United States

  • Investigative Site

    Maitland, Florida, 32751, United States

  • Investigative Site

    Miami, Florida, 33135, United States

  • Investigative Site

    Miami, Florida, 33165, United States

  • Investigative Site

    Winter Park, Florida, 32789, United States

  • Investigative Site

    Scarborough, Maine, 04074, United States

  • Investigative Site

    Farmington Hills, Michigan, 48334, United States

  • Investigative Site

    Abington, Pennsylvania, 19001, United States

  • Investigative Site

    Memphis, Tennessee, 38157, United States

  • Investigative Site

    Cypress, Texas, 77429, United States

  • Investigative Site

    Round Rock, Texas, 78681, United States

  • Investigative Site

    Spokane, Washington, 99202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.